HF
ELVN icon

HRT Financial’s Enliven Therapeutics ELVN Stock Holding History

HRT Financial’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,948
Closed -$36K – 2629
2022
Q3 		$36K Buy
+3,948
New +$23.3K ﹤0.01% 2461
2021
Q4 		– Sell
-5,800
Closed -$94K – 3388
2021
Q3 		$94K Buy
5,800
+321
+6% +$6.67K ﹤0.01% 2920
2021
Q2 		$173K Buy
+5,479
New +$170K ﹤0.01% 2444

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's ELVN Position: Q4 2022 in Review

HRT Financial sold out of Enliven Therapeutics (ELVN) in Q4 2022, closing a stake of 3,948 shares — an estimated $36K sold.

HRT Financial first reported a position in ELVN in Q2 2021 and held it in 3 quarters. The position peaked at $173K in Q2 2021. 36 funds tracked by Wall St. Rank hold ELVN as of Q4 2022.

  • HRT Financial reported no remaining Enliven Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HRT Financial sold 3,948 Enliven Therapeutics shares in Q4 2022, an estimated $36K.
  • HRT Financial first reported a position in Enliven Therapeutics in Q2 2021 and held it in 3 quarters.
  • HRT Financial's Enliven Therapeutics position peaked at $173K in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2022.

Based on HRT Financial's 13F filing for Q4 2022, filed 10 Feb 2023.